Pular para o conteúdo principal
Ranking Invest

AVXL - Anavex Life Sciences Corp.

Segmento: HealthcareAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Análise Ranking Invest

Valor de Mercado
$ 120.04 Mi
IVR
-0.03Índice proprietário de comparação relativa: -0,03.
IVR2
-1.07Leitura proprietária complementar: -107%.
MLL
-1.07Leitura proprietária complementar: -107%.
Último Balanço Atualizado: 3T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 112.45 Mi

Dívida Líquida

-$ 118.33 Mi

L4T

-$ 13.02 Mi

Indicadores Básicos

ROE

-11.58%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

D0.57

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

B7.85

Margem

D0.00

Índices de Endividamento

DIV/PAT

-1.05

DIV/L4T

9.09

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.